LONDON

伦敦

,

，

Sept. 17, 2026

2026年9月17日

/PRNewswire/ -- UK startup Eterna Regeneratives has closed a seed investment round led by Hoxton Ventures and The Venture Collective (TVC) to build its regenerative biomaterial platform spanning enamel repair and bone regeneration, starting with the

/美通社/ -- 英国初创公司Eterna Regeneratives已完成由Hoxton Ventures和The Venture Collective (TVC)领投的种子轮融资，旨在打造其再生生物材料平台，涵盖牙釉质修复和骨再生领域，起步于

$43bn

430亿美元

global oral care market. Co-founded by Khaled Eissa and Dr Sherif Elsharkawy in 2024, the King's College London spin-out attracted international attention last year when studies found the team's revolutionary patented material could successfully regrow damaged tooth enamel using keratin - a protein found in human hair, skin and wool.

全球口腔护理市场。该公司由Khaled Eissa和Sherif Elsharkawy博士于2024年联合创立，作为伦敦国王学院的衍生企业，去年因研究发现其团队革命性的专利材料能够利用角蛋白（一种存在于人类头发、皮肤和羊毛中的蛋白质）成功再生受损的牙釉质而受到国际关注。

The research developed by Dr Elsharkawy and Dr Sara Gamea, his PhD student, was picked up widely by national and international media, including from the BBC, Washington Post and Newsweek, putting keratin-based regeneration on the map well before a commercial product existed..

由埃尔沙卡维博士及其博士生萨拉·加梅亚博士开展的研究获得了国内外媒体的广泛报道，包括英国广播公司（BBC）、《华盛顿邮报》和《新闻周刊》等，这使得基于角蛋白的再生技术在商业化产品问世之前就已广受关注。

Continue Reading

继续阅读

Eterna Regeneratives Co-founders, Khaled Eissa (L) and Dr Sherif Elsharkawy (R)

Eterna Regeneratives 联合创始人，哈立德·伊萨（左）和谢里夫·埃尔沙卡维博士（右）

Now working to develop a pipeline of material technologies, Eterna aims to tackle a problem that affects nearly everyone: the slow, irreversible loss of tooth enamel. The team at Eterna Regeneratives believes that symptom management cannot be the only solution. 'The only way to truly heal the human body is to help it heal itself,' said Khaled Eissa, co-founder and CEO.

Eterna 目前正致力于开发一系列材料技术，旨在解决一个几乎影响每个人的问题：牙釉质缓慢且不可逆的流失。Eterna Regeneratives 团队认为，仅靠症状管理并非唯一的解决方案。“真正治愈人体的唯一途径是帮助其实现自我修复。”联合创始人兼首席执行官 Khaled Eissa 表示。

'We wanted to create a product that is readily available, scalable and has the potential to deliver long-term results.' 'This investment lets us move from lab-based proof of concept to real-world products at pace,' said Dr Sherif Elsharkawy, Chief Scientific Officer and co-founder. 'It is a validation of years of research, and a step change in how quickly we can bring this technology to patients.'.

“我们希望打造一款易于获取、具备可扩展性，并有望带来长期成效的产品。”首席科学官兼联合创始人谢里夫·埃尔沙卡维博士表示：“这笔投资使我们能够加速从实验室阶段的概念验证迈向现实世界中的产品化。这是对我们多年研究的认可，也标志着我们将该技术应用于患者群体的速度实现了质的飞跃。”

Unlike many other tissues in the human body, tooth enamel cannot naturally regenerate once it has been lost. This can lead to hypersensitivity, cavities, tooth pain and the gradual deterioration of teeth. Fluoride, the best option currently available on the market, only superficially addresses the problem – offering minor strengthening of existing enamel but failing to rebuild what has already been lost.

与人体许多其他组织不同，牙釉质一旦丧失便无法自然再生。这可能导致牙齿敏感、龋齿、牙痛以及牙齿的逐渐恶化。氟化物是目前市场上最佳的现有选择，但仅能表面性地缓解问题——它只能轻微强化现有的牙釉质，却无法重建已经丧失的部分。

Resin, the go-to for professional repair, merely fills a tooth rather than rebuilding it, and has a finite lifespan, often resulting in necessary replacements and high costs for patients. It is against this backdrop that Eterna has created a keratin-based material that can be added to toothpaste, enabling cost-effective and lasting enamel regeneration..

树脂作为专业修复的首选材料，仅能填充牙齿而非重建牙齿，且使用寿命有限，往往导致患者需要反复更换并承担高昂费用。在此背景下，Eterna 研发出一种基于角蛋白的材料，可添加于牙膏中，从而实现经济高效且持久的牙釉质再生。

Eterna's patented keratin-based product has delivered striking results. In vitro experiments carried out on extracted tooth samples revealed a new, enamel-like layer forming directly on the tooth surface, as the material stimulates a mineralisation process. Treated samples showed hardness and mechanical strength restored to levels close to that of native, healthy enamel.

Eterna的专利角蛋白基产品已展现出显著效果。在提取的牙齿样本上进行的体外实验显示，由于该材料能够刺激矿化过程，牙齿表面直接形成了一层新的类釉质层。经过处理的样本显示出，其硬度和机械强度已恢复至接近天然健康牙釉质的水平。

Moreover, the technology has shown the capacity to reduce abrasion and even treat decay. This provides a first glimpse into what it might look like to help a tooth heal itself, instead of simply patching over damage. It is also significantly cheaper than alternatives, delivering meaningful treatment at a fraction of the cost..

此外，该技术已展现出减少磨损甚至治疗龋齿的能力。这让我们首次得以窥见，如何帮助牙齿实现自我修复，而非仅仅对损伤进行填补。与替代方案相比，其成本也显著更低，能够以极低的费用提供具有实质意义的治疗。

Hussein Kanji, Partner at Hoxton Ventures

侯赛因·坎吉，Hoxton Ventures 合伙人

'Eterna is the kind of company we like to back early: powerful, defensible science with a capital-efficient route to market. Its technology has the potential to transform oral care from managing enamel loss to actually repairing it, while opening the door to broader applications in tissue and bone regeneration.

Eterna 正是我们喜欢早期投资的那类公司：拥有强大的、具备防御性的科学基础，并以资本高效的方式走向市场。其技术有望将口腔护理从单纯管理牙釉质流失转变为真正修复牙釉质，同时为组织和骨骼再生等更广泛的应用领域打开大门。

Khaled and Sherif are the right scientific team to bring this from the lab and to global scale.'.

“哈立德和谢里夫是将这一成果从实验室推向全球规模的合适科研团队。”

Gina Kirch, Founding Partner at The Venture Collective:

吉娜·基尔希，The Venture Collective 创始合伙人：

'

'

Eterna is looking beyond basic healing to achieve complete tissue restoration. For too long, patients have had to settle for treatments that manage damage rather than repair it. Eterna is revolutionizing this standard of care, harnessing its patented keratin technology to help the body regenerate itself more fully than existing options allow..

Eterna 不满足于基础的愈合效果，而是致力于实现完整的组织修复。长期以来，患者只能接受那些仅能控制损伤而非真正修复损伤的治疗方案。Eterna 正在彻底改变这一护理标准，凭借其专利角蛋白技术，帮助机体实现比现有疗法更为全面的自我再生。

'

'

Eterna's second application will build on the same patented knowledge, this time targeting bone regeneration. Today, when someone breaks a bone, soft tissue grows back into the site without resolving the underlying fragility. Medical solutions typically involve inserting a collagen membrane and hoping the bone regrows.

Eterna的第二项应用将基于同样的专利技术，这次的目标是促进骨骼再生。目前，当有人骨折时，软组织会重新长入受伤部位，但并未解决根本的脆弱性问题。现有的医疗解决方案通常涉及植入胶原膜，并寄希望于骨骼能够自行再生。

But preliminary tests suggest Eterna's keratin-based technology could be harnessed to regenerate strong, healthy bone..

但初步测试表明，Eterna的角蛋白技术有望被用于再生强健、健康的骨骼。

Oral health is Eterna's first commercial beachhead, with further IP in the pipeline beyond bone regeneration. The company is expanding its research and commercial teams and building relationships with oral-care companies, professional partners and consumer-health groups, with a clear focus on delivering its first commercial product in the near term.

口腔健康是Eterna公司的首个商业化切入点，除骨骼再生外，公司还有更多知识产权储备正在推进中。Eterna正在扩大其研究和商业团队，并与口腔护理公司、专业合作伙伴以及消费者健康群体建立合作关系，明确专注于在近期推出其首款商业化产品。

By embedding its material into products already on the market, Eterna aims to bring its sophisticated but accessible science directly to consumers..

通过将自身材料嵌入已上市的产品中，Eterna 旨在将其复杂但易于理解的科学成果直接带给消费者。

About Eterna

关于 Eterna

Eterna Regeneratives is a UK biotechnology spin-out from King's College London, founded in 2024 by Khaled Eissa and Sherif Elsharkawy. Backed by Hoxton Ventures and The Venture Collective, Eterna is building a biomaterials platform for mineralisation and tissue regeneration, with initial applications in enamel repair and bone.

Eterna Regeneratives 是一家源自伦敦国王学院的英国生物技术衍生公司，由 Khaled Eissa 和 Sherif Elsharkawy 于 2024 年创立。在 Hoxton Ventures 和 The Venture Collective 的支持下，Eterna 正在打造一个用于矿化和组织再生的生物材料平台，初步应用于牙釉质修复和骨骼领域。

Their patented platform uses keratin, derived from sheep's wool, to guide new mineral growth at the site of damage, working with the body's own chemistry beyond just protection. The company has now grown into a new lab space in Canary Wharf, where they are focused on commercialising their product, building their IP pipeline, and partnering with healthcare companies to bring their product to the mass market..

他们的专利平台利用从羊毛中提取的角蛋白，在受损部位引导新的矿物质生长，不仅提供保护，还与人体自身的化学机制协同作用。该公司现已迁至金丝雀码头的新实验室空间，专注于产品的商业化、构建知识产权管线，并与医疗健康公司合作，将产品推向大众市场。

SOURCE Eterna Regeneratives Ltd

来源：Eterna Regeneratives Ltd

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示